Publication at Faculty of Medicine in Hradec Králové |
2017
Abstract
Alemtuzumab is a drug used in the treatment of relapsing-remitting multiple sclerosis in Czech Republic. Alemtuzumab has a new mechanism of action and pharmacokinetic profile with no clinically relevant drug-drug interactions.
The efficacy of alemtuzumab has been shown in clinical trials. This drug has significant anti-inflammatory effect, reduces the number of relapses and also has positive effect on radiological parametres.
Common adverse event is acquired autoimmune disease.